The development of immune checkpoint inhibitors, including programmed death-1 and programmed death-ligand 1 (PD-L1) inhibitors, has changed the treatment methods for non—small cell lung cancer (NSCLC). There may be potential interchangeability of the clinical use of certain PD-L1 inhibitors on tumor cell membranes for NSCLC, but not for assessment of PD-L1 expression on immune cells, according to a study.
In a study, published by the Journal of Clinical Oncology, reviewed previously published studies from January 2016 to January 2017 on clinical trial and laboratory-developed PD-L1 immunohistochemistry (IHC) assays (LDAs). The researchers analyzed the effects of diagnostic methods on PD-L1 expression levels in the studies in order to address the practical issues related to tissue samples.
Use of pembrolizumab to treat NSCLC requires PD-L1 IHC testing, but nivolumab and atezolizumab are approved without testing. However, the FDA has approved complimentary PD-L1 tests for both.
“Although PD-L1 IHC testing has value as a biomarker, it has limitations. Research is ongoing to identify novel biomarkers that could be used alone or in combination with PD-L1 expression levels to improve patient selection for immunotherapy,” the researchers concluded.
Following the review, the researchers found that high concordance and interobserver reproducibility were present with the PD-L1 IHC 28-8 pharmDx, PD-L1 IHC 22C3 pharmDx, and Ventana PD-L1 SP263 clinical trial assays for PD-L1 expression on tumor cell membranes. For lower PD-L1 expression was detected with Ventana PD-L1 SP142. Additionally, immune-cell PD-L1 expression was variable and interobserver concordance was poor. Researchers also noted the variable effects on PD-L1 expression for inter- and intraturmoral heterogeneity.
The researchers suggested that the development of LDAs requires standardization before they are used for recommendations in routine clinical use. In addition, the authors noted a need for training or specialized pathologists.
“Interpretation of PD-L1 IHC assays differs from most other IHC assays in the need for appreciation and understanding of the often-heterogeneous morphology of pulmonary tumors,” the authors noted. “Therefore, specialized training is important to maintain consistency and quality of interpretation between pathologists.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More